On November 29, 2011, Medunik Canada has announced the conclusion of a strategic collaboration agreement with QOL Medical LLC. Under this agreement, Medunik Canada will work at optimizing the introduction and distribution of orphan drugs on the Canadian market, including the regulatory approval strategy and post-approval activities for two therapeutic options: Congenital Sucrase-Isomaltase Deficiency (CSID) and esophageal varices.

Congenital Sucrase-Isomaltase Deficiency (CSID) is a chronic, autosomal recessive, inherited disease. CSID is usually characterized by a complete or almost complete lack of endogenous sucrase activity, a very marked reduction in isomaltase activity, a moderate decrease in maltase activity and normal lactase levels.

CSID may lead to malnutrition. Undiagnosed/untreated CSID patients often fail to thrive and fall behind in their expected growth and development curves.

Esophageal varices are dilated blood vessels usually in the esophagus or stomach. They cause no symptoms unless they rupture and bleed. Bleeding from varices is a life-threatening complication of portal hypertension. Portal hypertension is an increase in the pressure within the portal vein (the vein that carries blood from the digestive organs to the liver) due to blockage of blood flow throughout the liver. This increased pressure in the portal vein causes the development of large, swollen veins (varices) within the esophagus and stomach. The varices are fragile and can rupture easily, resulting in a large amount of blood loss. The most common cause of portal hypertension is cirrhosis of the liver.